Guangshengtang announced that in the first half of 2026, it achieved operating income of 209 million yuan, a year-on-year decrease of 5.13%; a net loss attributable to shareholders of listed companies was 666.881 million yuan, a net loss of 708.378 million yuan after deducting non-recurring profit and loss. Basic earnings per share - 0.4187 yuan, weighted average return on net assets - 20.40%. Net assets attributable to shareholders of listed companies at the end of the reporting period were $1,339 million, down 4.40% from the end of the previous year. During the reporting period, a major national science and technology project for hepatitis B treatment involving Guangsheng Zhonglin, the innovative pharmaceutical subsidiary of the company, was approved; the phase III clinical trial of the innovative hepatitis B drug Nericovir GST-HG141 completed the enrollment of all 578 subjects; the issuance of A-shares to specific targets was completed, and the actual net capital raised was 710 million yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.